Hantech Bio-Technology Co (1294) Fair Value & Analysis
Consumer Defensive · TW · Market cap 2.4B TWD
Fair value as of: Jun 24, 2026
Analysis
Hantech Bio-Technology Co (1294) currently trades at 78.70 TWD, while our model-based Fair Value estimate is 87.02 TWD — implying the stock looks roughly 10.6% undervalued today. We read business quality at 95/100 (high quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Hantech Bio-Technology Co., Ltd., through its subsidiaries, engages in the manufacture, trade in, and distributes biotech foods, health foods, and Traditional Chinese Medicine skincare and beauty products in Taiwan and internationally. The company offers OEM & ODM manufacturer of liquid, jelly, and gel-type health supplements. It also provides aluminum foil bag designs; and aluminum foil-packaged beverage production activities. In addition, the company is involved in the manufacture of machinery and equipment; and trade in of health food raw materials. It serves clients across both online and offline channels, including direct sales, micro-businesses, physical stores (pharmacies/drugstores/beauty shops), TV, radio, telemarketing centers, TV shopping, online shopping, and live-stream shopping. Hantech Bio-Technology Co., Ltd. was founded in 2007 and is based in Changhua, Taiwan.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Hantech Bio-Technology Co (1294) undervalued?
What is the fair value of 1294?
What is the quality score of 1294?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.